Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies

Bioorg Med Chem. 2020 Aug 1;28(15):115599. doi: 10.1016/j.bmc.2020.115599. Epub 2020 Jun 20.

Abstract

Cancer is a leading cause of death worldwide. Even after the availability of numerous drugs and treatments in the market, scientists and researchers are focusing on new therapies because of their resistance and toxicity issues. The newly synthesized drug candidates are able to demonstrate in vitro activity but are unable to reach clinical trials due to their rapid metabolism and low bioavailability. Therefore there is an imperative requisite to expand novel anticancer negotiators with tremendous activity as well as in vivo efficacy. Tetrazole is a promising pharmacophore which is metabolically more stable and acts as a bioisosteric analogue for many functional groups. Tetrazole fragment is often castoff with other pharmacophores in the expansion of novel anticancer drugs. This is the first systematic review that emphasizes on contemporary strategies used for the inclusion of tetrazole moiety, mechanistic targets along with comprehensive structural activity relationship studies to provide perspective into the rational design of high-efficiency tetrazole-based anticancer drug candidates.

Keywords: Bioavailability; Mechanism; Pharmacophore; SAR; Synthesis; Tetrazole.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors
  • Molecular Structure
  • Neoplasms / drug therapy*
  • Structure-Activity Relationship
  • Tetrazoles / chemical synthesis
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Tetrazoles